Investor Presentaiton

Investor Presentation First nine months of 2018 Slide 93 SaxendaⓇ now launched in 37 countries SaxendaⓇ value share of anti-obesity medications in selected countries Mexico Germany 100% 80% 60% 40% 20% Australia Italy Belgium USA Brazil UAE Canada Denmark Spain DKK SaxendaⓇ sales in first nine months of 2018¹ Saxenda local currency growth million 3,000 53% Operations IO Regions 2,500 2,000 31% 1,500 1,000 500 139% 201% 69% 121% 0% 0 5 10 15 20 Months from Launch 25 30 35 40 Source: IQVIA Aug 2018 Note: The market for anti-obesity medication varies significantly in size between countries changing diabetes Total NAO IO Region Region Region AAMEO LATAM Europe NAO: North America Operations; AAMEO: Africa, Asia, Middle East & Oceania; LATAM: Latin America; J&K: Japan & Korea 1 Reported sales for first nine months of 2018 SaxendaⓇ was launched in South Korea within Region Japan & Korea during 2018

View entire presentation